BioSpace News Archive

Adial Pharmaceuticals, Inc. today announced it has reached the 35% enrollment target in the Company’s landmark ONWARD™ Phase 3 pivotal trial in Europe. ONWARD™ is investigating the efficacy and safety of Adial’s lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD)

Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (" Tiziana " or the " Company "), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares (“Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the “Official List”) and admission to trading on the London Stock Exc

Next Generation System Provides Efficiency-Focused Workflow Enhancements, Pathology Engine, and PENTAX Connect Compatibility

An orthopedic surgeon at Hospital for Special Surgery has performed the first augmented reality knee replacement in the United States.

After an extensive and rigorous search, The Myositis Association (TMA) is thrilled to announce that Chrissy Thornton will be joining the Association as Executive Director. In this position, Chrissy will be responsible for the operation of the organization as it fulfills its mission to improve the lives of persons affected by my

The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Steve Cutler, Chief Executive Officer of ICON, as Chair effective January 1, 2021. Jackie Kent, Executive Vice President and Head of Product at Medidata Solutions, was elected Vice Chair. The Board of Directors also elected Ari Feldman, Vice President, Global Compliance and Strategy at Medidata Solutions,

Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal activities. She will report directly to the company’s CEO. Sarah rejoins Psychemedics from Decibel Therapeutics, Inc., a biotech start-up researching hearing loss therapeutics, and Takeda Pharmaceutical Company, Ltd.

The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disea

CCT Research, a leader in community-based, embedded clinical research, announced the expansion of its clinical trial operations to the Las Vegas metropolitan area.